Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo CEO Takes Faith In Rx Generics Business To Exit Door With Him

Executive Summary

Private label OTC business is likely to be strengthened as Perrigo’s core, as CEO Hendrickson announces retirement shortly after hedge fund investor Starboard Value, pushing to divest the Rx business, built a five-seat block on Perrigo's board.

Advertisement

Related Content

Perrigo Expanding Consumer Portfolio After Finding Problems Slowing Growth
Another Change At Perrigo Helm As Results Remain Turbulent
Another Change At Perrigo Helm As Results Remain Turbulent
Another Change At Perrigo Helm As Results Remain Turbulent
Perrigo Finding Balance As Three-Legged Stool With Two Consumer Units, Rx Division
Perrigo Finding Balance As Three-Legged Stool With Two Consumer Units, Rx Division
Amazon OTCs Likely A Worry For Retailers, A Remedy For Perrigo
Perrigo Closes Q1 Earnings Saga Trying To Keep Grip On Rx Business
Perrigo Trims Workforce, Ships Tysabri License, Stays European Course
Perrigo OTC Brand Journey Detours Into Management, Operating Problems

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS120806

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel